Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

The Systemic Effects of Vorinostat in Patients (Pts) with Cutaneous T-Cell Lymphoma (CTCL): Post-Hoc Analyses in Pts with High Blood Tumor Burden.

Madeleine Duvic, MD, Youn H Kim, MD, Timothy M Kuzel, MD, Theresa R Pacheco, MD, Francine M Foss, Sareeta Parker, Syed Rizvi, Cong Chen, Jean Marie Arduino, ScD, Elise A. Olsen, MD

Blood (2009) 114 (22): 1709.

https://doi.org/10.1182/blood.V114.22.1709.1709

Published: 2009

Journal Articles

Is Skull-Base to Proximal Thigh PET/CT Enough? Do We Need Vertex to Toe PET/CT Imaging for Cutaneous T-Cell Lymphoma (CTCL) Patients?.

Catherine S Woodward, Nassoma King, PA, Kenneth Prince, Sareeta Parker, Raghuveer Halkar, Mary Jo Lechowicz, MD

Blood (2009) 114 (22): 5020.

https://doi.org/10.1182/blood.V114.22.5020.5020

Published: 2009

Journal Articles

FDG PET in the Staging and Management of Cutaneous T Cell Lymphoma

Catherine S Woodward, Raghuveer Halkar, Keith Delman, Sareeta Parker, Nassoma King, Mary Jo Lechowicz

Blood (2008) 112 (11): 5298.

https://doi.org/10.1182/blood.V112.11.5298.5298

Published: 2008

Journal Articles

Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Provides Prolonged Safety and Clinical Benefit to Patients with Advanced Cutaneous T-Cell Lymphoma (CTCL).

Madeleine Duvic, Elise A. Olsen, Debra Breneman, Theresa R. Pacheco, Sareeta Parker, Eric C. Vonderheid, Justin L. Ricker, Syed Rizvi, Cong Chen, Kathleen Boileau, Paulette Cooley, Larisa J. Geskin

Blood (2007) 110 (11): 2582.

https://doi.org/10.1182/blood.V110.11.2582.2582

Published: 2007

Journal Articles

Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Provides Prolonged Clinical Benefit to Advanced Cutaneous T-Cell Lymphoma Patients: Updated Results of the Phase IIb Multicenter Clinical Trial.

Madeleine Duvic, MD, Youn H. Kim, MD, Timothy M. Kuzel, MD, Theresa R. Pacheco, MD, Francine M. Foss, MD, Sareeta Parker, MD, Stanley R. Frankel, MD, Cong Chen, PhD, Justin L. Ricker, MD, PhD, Jean Marie Arduino, PhD, Sophia Randolph, MD, PhD, Victoria M. Richon, PhD, Elise A. Olsen, MD

Blood (2006) 108 (11): 399.

https://doi.org/10.1182/blood.V108.11.399.399

Published: 2006

NARROW

The Systemic Effects of Vorinostat in Patients (Pts) with Cutaneous T-Cell Lymphoma (CTCL): Post-Hoc Analyses in Pts with High Blood Tumor Burden.

Is Skull-Base to Proximal Thigh PET/CT Enough? Do We Need Vertex to Toe PET/CT Imaging for Cutaneous T-Cell Lymphoma (CTCL) Patients?.

FDG PET in the Staging and Management of Cutaneous T Cell Lymphoma

Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Provides Prolonged Safety and Clinical Benefit to Patients with Advanced Cutaneous T-Cell Lymphoma (CTCL).

Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Provides Prolonged Clinical Benefit to Advanced Cutaneous T-Cell Lymphoma Patients: Updated Results of the Phase IIb Multicenter Clinical Trial.

Email alerts

ASH Publications

American Society of Hematology

The Systemic Effects of Vorinostat in Patients (Pts) with Cutaneous T-Cell Lymphoma (CTCL): Post-Hoc Analyses in Pts with High Blood Tumor Burden.

Is Skull-Base to Proximal Thigh PET/CT Enough? Do We Need Vertex to Toe PET/CT Imaging for Cutaneous T-Cell Lymphoma (CTCL) Patients?.

FDG PET in the Staging and Management of Cutaneous T Cell Lymphoma

Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Provides Prolonged Safety and Clinical Benefit to Patients with Advanced Cutaneous T-Cell Lymphoma (CTCL).

Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Provides Prolonged Clinical Benefit to Advanced Cutaneous T-Cell Lymphoma Patients: Updated Results of the Phase IIb Multicenter Clinical Trial.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only